Savara(NASDAQ) SVRA

Savara develops treatments for rare lung diseases affecting breathing. Its main drug aims to help people with a specific lung disorder. The company focuses on patients with limited treatment options.

Breathe Easy: Products and Services

• MOLBREEVI (molgramostim inhalation solution): Inhaled drug for autoimmune pulmonary alveolar proteinosis (autoimmune PAP), a rare lung disease; 100% of pipeline focus.
• Clinical Development Services: Designs and manages clinical trials for MOLBREEVI; targets patients and healthcare providers.
• Regulatory Affairs: Handles approval processes with health authorities; supports future product launch.
• Contract Manufacturing: Partners with third parties to produce MOLBREEVI and its delivery device.

Growth Spurts: Expansion and Partnerships

• Entered manufacturing partnership with FujiFilm Diosynth for drug production in 2024.
• Formed device partnership with PARI Pharma GmbH for a proprietary nebulizer.
• Launched pediatric clinical trial (IMPACT) for autoimmune PAP in 2024.
• Submitted Biologics License Application to FDA in 2025; plans resubmission after data request.

What Makes Savara Stand Out

Savara focuses on a single rare lung disease, concentrating all resources on one drug. The company uses an outsourced model, keeping its workforce lean and costs flexible. Regulatory designations from US and European agencies highlight its niche approach.

Five Things You Need to Know

• No product revenue reported for Q2 2025, Q2 2024, or Q2 2023.
• Net loss was $30.4 million in Q2 2025, up 36.7% from Q2 2024.
• Operating expenses reached $31.4 million in Q2 2025, up 35.6% year-over-year.
• Cash and short-term investments totaled $146.4 million as of June 30, 2025.

Bottom Line

Savara is a focused biotech company with one drug in late-stage development. Its future depends on regulatory progress and successful commercialization of its lead therapy.